Nano PharmaSolutions will be at PharmSci360 in Salt Lake City and will present Nano-CNS powder nasal spray delivery platform technology with the animal PK data. Please message me if you would like to connect.
NanoPharmaSolutions, Inc.
制药业
San Diego，California 848 位关注者
Phase-transition technology platform for enhancing solubility of BCS 2 & 4 APIs without the use of exogenous chemicals
关于我们
Nano PharmaSolutions (NPS) has developed the platform nanodrug delivery technology, NanoTransformer? that generates nanoparticles of small molecule drugs without using lipids or polymers. NanoTransformer is the only drug nanoparticle generation process that uses phase-transition technology to enhance the solubility of BCS 2 and BCS 4 APIs without the use of excipients. The cGMP manufacturing facility opens in 2024. Nano PharmaSolutions delivers CNS therapeutics through nose to bring delivery using NanoTransformer process. This clean nanotechnology can safely and effectively deliver drugs to brain through the nose because it doesn't contain other chemicals for nanoengineering.
- 网站
-
https://www.nanopharmasolutions.com
NanoPharmaSolutions, Inc.的外部链接
- 所属行业
- 制药业
- 规模
- 2-10 人
- 总部
- San Diego，California
- 类型
- 私人持股
- 创立
- 2019
地点
-
主要
获取路线
9853 Pacific Heights Blvd
Suite O
US，California，San Diego，92121
NanoPharmaSolutions, Inc.员工
动态
-
Nano Pharma Solutions is ready for GMP production of its N-granule? (drug nanoparticles on mannitol base) using groundbreaking nanotechnology with in-line MS (mass spectroscopy) detector at its strategic partner Mikart, LLC (Atlanta, GA).?Please contact [email protected] for appointment to tour the facility and discuss collaboration for your poorly soluble drugs. ?
-
-
Nano PharmaSolutions is honored to be selected as the success case study by the San Diego regional EDC, #WTCSD. read here: https://lnkd.in/grn6n4TR
-
-
Nano PharmaSolutions is thrilled to introduce interim Chief Operating Officer, William Martin. Bill has 15 years of experience in drug development, working to grow innovative companies by securing financing and strategic partnerships. Bill brings a unique perspective, combining financial expertise with operational excellence to NPS as we embark on our first clinical trial of NT-301 for Parkinson's Disease.
-
-
Parkinson's Disease affects one million people in USA It is second most prevalent neurodegenerative disease according to the CDC. It is estimated that, by year 2037, the number of people with Parkinson's in USA will nearly double. Nano PharmaSolutions stands with the patients and caregivers of Parkinson's Disease.
-
-
Please join us at Medtech/Life Science MeetUp in Irvine on April 17th (in person or virtual) where Nano PharmaSolutions will present the Nano-CNS technology. See detail here: https://lnkd.in/gzdcgVBk #nanopharmasolutions, #nanodrugdelivery
-